News from Visiopharm

Visiopharm User Group Meeting 2018 - Augment your Pathology

User Group Meeting Denmark
February 28 - Marts 1, 2018

Sign up: here

Agenda: here

User Group Meeting US
June 5 - 6, 2018

Sign up: here

Webinar - Introducing Oncotopix AI

March 7th, 2018

15:00-16:00 CET, 9:00-10:00 AM EST, 6:00-7:00 AM PST

Artificial intelligence and deep learning are probably the hottest keywords of 2017 within the healthcare research community, strongly driven by amazing state-of-the-art results in computer vison and natural language processing combined with popular media interest.

Sign up here



New APP: Ki-67, Epidermal Hyperplasia

The Ki-67 protein is expressed in the nucleus and is a marker for cell proliferation. Increased number of Ki-67 positive cells in epidermis indicates increased epidermal hyperplasia, a characteristic which is associated with various inflammatory skin diseases as atopic dermatitis and psoriasis.

This protocol can be used to assess the number of Ki-67 positive cells in epidermis. The protocol provides the number and area of Ki-67 positive cells within the epidermis region, as well as for the entire tissue section. Manual assessment of the outlined epidermis region can be necessary.

For more information visit our APP Center

New APP: PD-L1, Cell Lines, Cancer

This APP can be used for quality control of PD-L1 strong positive, intermediate positive, weak positive and negative cell line material to ensure that each cell line block complies with the expected PD-L1 expression before the material is used as reference standard for IHC assays. The APP quantifies the PD-L1 expression in each cell line core and relates this expression to a known reference value for each cell line expression level.

For more information visit our APP Center

Sign up to our newsletter
* indicates required
Are you a current customer

Visiopharm quantitative digital pathology solutions provide pathologists and scientists with a flexible, powerful suite of software to quantify relevant tissue properties in a fast, objective and reproducible way.

Learn more about us

Visit our APP center

The worlds largest and fastest growing

Visit the complete app center


Visiopharm software is featured in over 1200 international scientific publications. They are based on collaborations with leading scientists in hospitals, biopharmaceutical companies and research institutions around the world. Select a main category to access the publication list.